This Mvabea market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Growth during the historic period can be attributed to rising incidences of pests and diseases, a greater emphasis on soil health and fertility, advancements in biotechnology research, heightened focus on food safety standards, and increased early government subsidies for agriculture.
Growth during the forecast period can be attributed to the expansion of organic farming, the rise of urban agriculture, increased emphasis on water conservation, the establishment of agricultural cooperatives, and the growth of agribusiness corporations. Key trends anticipated during this period include advancements in vaccine development, the adoption of longitudinal health monitoring, the establishment of ethical frameworks for vaccine distribution, the development of cross-protection vaccines, and the integration of genomic technologies.
The increasing incidence of Ebola is anticipated to drive the growth of the MVABEA market. Ebola is a highly contagious and often fatal disease caused by the Ebola virus, which belongs to the filovirus family. The rise in Ebola cases can be attributed to factors such as more frequent human-wildlife interactions, urbanization, weak healthcare systems, and difficulties in rapidly detecting and responding to outbreaks. MVABE (Monoclonal Vaccine Against Ebola) plays a key role in combating the disease by providing targeted immunity through antibodies that specifically bind to and neutralize the Ebola virus. This helps prevent infection or lessen its severity in individuals exposed to the virus. For example, in May 2024, the Centers for Disease Control and Prevention reported an Ebola virus disease (EVD) outbreak in Uganda caused by the Sudan ebolavirus. As of November 2022, there were 136 confirmed cases and 53 deaths, including 18 infections and seven fatalities among healthcare workers. The rising incidence of Ebola is driving the growth of the MVABEA market.
The growth of the MVABEA market is also expected to be propelled by the expansion of vaccination programs. These programs are vital for preventing the spread of infectious diseases, protecting vulnerable populations, enhancing community immunity, and improving overall public health. They also help reduce healthcare costs and promote better health outcomes. In the context of MVABEA, vaccination programs play a significant role in improving disease prevention, addressing vaccine accessibility in underserved areas, and strengthening healthcare systems through education and infrastructure. For example, a report by the Australian Institute of Health and Welfare in July 2024 showed an increase in influenza vaccine coverage from 2021 to 2022 across all adult age groups. Coverage rose from 23.9% to 30.5% for those aged 20-49, from 38.2% to 46.8% for those aged 50-64, from 62.1% to 67.5% for those aged 65-74, and from 68.5% to 73% for those aged 75 and older. This expansion of vaccination programs is contributing to the growth of the MVABEA market.
A significant development in the MVABEA market is the regulatory approval of its vaccine for adolescents aged 12 to 17 years. Regulatory approvals are formal authorizations granted by government or regulatory bodies that allow a medical product to be marketed and used. For instance, in September 2024, Bavarian Nordic, a Denmark-based biotechnology company, received approval from the FDA and EMA for its mpox vaccine, Imvanex (MVA-BN), for use in the 12-17 age group. The MVA-BN vaccine, marketed under the names JYNNEOS, IMVAMUNE, and IMVANEX, is a non-replicating live virus vaccine suitable for immunocompromised individuals. It is approved for both mpox and smallpox prevention, demonstrating about 76% effectiveness with one dose and over 80% with two doses. It is authorized for adults aged 18 and older, with emergency use granted for high-risk adolescents aged 12 to 17. The vaccine can be stored for up to eight weeks at 2-8 degrees Celsius and has a favorable safety profile, with mild to moderate side effects.
The key player in the mvabea market is Johnson & Johnson.
North America was the largest region in the mvabea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mvabea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mvabea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Mvabea is part of a two-dose Ebola vaccine regimen designed to protect against the Zaire Ebola virus species. It is administered as the second dose in conjunction with Zabdeno (Ad26.ZEBOV) to boost the immune response. Mvabea employs a modified vaccinia Ankara (MVA) vector to deliver viral proteins and stimulate an immune defense.
The primary product types of Mvabea include Mvabea (MVA-BN-Filo) and Zabdeno (Ad26.ZEBOV). Mvabea specifically targets the prevention of Ebola virus disease caused by Zaire ebolavirus. Its applications encompass disease prevention and outbreak control, with end users including government organizations, healthcare providers, and research institutions.
The mvabea market research report is one of a series of new reports that provides mvabea market statistics, including mvabea industry global market size, regional shares, competitors with a mvabea market share, detailed mvabea market segments, market trends and opportunities, and any further data you may need to thrive in the mvabea industry. This mvabea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mvabea market consists of sales of ebola vaccine regimens in combination with Zabdeno (Ad26.ZEBOV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Growth during the historic period can be attributed to rising incidences of pests and diseases, a greater emphasis on soil health and fertility, advancements in biotechnology research, heightened focus on food safety standards, and increased early government subsidies for agriculture.
Growth during the forecast period can be attributed to the expansion of organic farming, the rise of urban agriculture, increased emphasis on water conservation, the establishment of agricultural cooperatives, and the growth of agribusiness corporations. Key trends anticipated during this period include advancements in vaccine development, the adoption of longitudinal health monitoring, the establishment of ethical frameworks for vaccine distribution, the development of cross-protection vaccines, and the integration of genomic technologies.
The increasing incidence of Ebola is anticipated to drive the growth of the MVABEA market. Ebola is a highly contagious and often fatal disease caused by the Ebola virus, which belongs to the filovirus family. The rise in Ebola cases can be attributed to factors such as more frequent human-wildlife interactions, urbanization, weak healthcare systems, and difficulties in rapidly detecting and responding to outbreaks. MVABE (Monoclonal Vaccine Against Ebola) plays a key role in combating the disease by providing targeted immunity through antibodies that specifically bind to and neutralize the Ebola virus. This helps prevent infection or lessen its severity in individuals exposed to the virus. For example, in May 2024, the Centers for Disease Control and Prevention reported an Ebola virus disease (EVD) outbreak in Uganda caused by the Sudan ebolavirus. As of November 2022, there were 136 confirmed cases and 53 deaths, including 18 infections and seven fatalities among healthcare workers. The rising incidence of Ebola is driving the growth of the MVABEA market.
The growth of the MVABEA market is also expected to be propelled by the expansion of vaccination programs. These programs are vital for preventing the spread of infectious diseases, protecting vulnerable populations, enhancing community immunity, and improving overall public health. They also help reduce healthcare costs and promote better health outcomes. In the context of MVABEA, vaccination programs play a significant role in improving disease prevention, addressing vaccine accessibility in underserved areas, and strengthening healthcare systems through education and infrastructure. For example, a report by the Australian Institute of Health and Welfare in July 2024 showed an increase in influenza vaccine coverage from 2021 to 2022 across all adult age groups. Coverage rose from 23.9% to 30.5% for those aged 20-49, from 38.2% to 46.8% for those aged 50-64, from 62.1% to 67.5% for those aged 65-74, and from 68.5% to 73% for those aged 75 and older. This expansion of vaccination programs is contributing to the growth of the MVABEA market.
A significant development in the MVABEA market is the regulatory approval of its vaccine for adolescents aged 12 to 17 years. Regulatory approvals are formal authorizations granted by government or regulatory bodies that allow a medical product to be marketed and used. For instance, in September 2024, Bavarian Nordic, a Denmark-based biotechnology company, received approval from the FDA and EMA for its mpox vaccine, Imvanex (MVA-BN), for use in the 12-17 age group. The MVA-BN vaccine, marketed under the names JYNNEOS, IMVAMUNE, and IMVANEX, is a non-replicating live virus vaccine suitable for immunocompromised individuals. It is approved for both mpox and smallpox prevention, demonstrating about 76% effectiveness with one dose and over 80% with two doses. It is authorized for adults aged 18 and older, with emergency use granted for high-risk adolescents aged 12 to 17. The vaccine can be stored for up to eight weeks at 2-8 degrees Celsius and has a favorable safety profile, with mild to moderate side effects.
The key player in the mvabea market is Johnson & Johnson.
North America was the largest region in the mvabea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mvabea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mvabea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Mvabea is part of a two-dose Ebola vaccine regimen designed to protect against the Zaire Ebola virus species. It is administered as the second dose in conjunction with Zabdeno (Ad26.ZEBOV) to boost the immune response. Mvabea employs a modified vaccinia Ankara (MVA) vector to deliver viral proteins and stimulate an immune defense.
The primary product types of Mvabea include Mvabea (MVA-BN-Filo) and Zabdeno (Ad26.ZEBOV). Mvabea specifically targets the prevention of Ebola virus disease caused by Zaire ebolavirus. Its applications encompass disease prevention and outbreak control, with end users including government organizations, healthcare providers, and research institutions.
The mvabea market research report is one of a series of new reports that provides mvabea market statistics, including mvabea industry global market size, regional shares, competitors with a mvabea market share, detailed mvabea market segments, market trends and opportunities, and any further data you may need to thrive in the mvabea industry. This mvabea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mvabea market consists of sales of ebola vaccine regimens in combination with Zabdeno (Ad26.ZEBOV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Mvabea Market Characteristics4. Mvabea Market Trends and Strategies5. Mvabea Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Mvabea Pricing Analysis & Forecasts30. Global Mvabea Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Mvabea Market32. Recent Developments in the Mvabea Market
3. Mvabea Market Biologic Drug Characteristics
6. Global Mvabea Growth Analysis and Strategic Analysis Framework
8. Mvabea Market Segmentation
9. Global Mvabea Epidemiology of Clinical Indications
10. Mvabea Market Regional and Country Analysis
11. Asia-Pacific Mvabea Market
12. China Mvabea Market
13. India Mvabea Market
14. Japan Mvabea Market
15. Australia Mvabea Market
16. South Korea Mvabea Market
17. Western Europe Mvabea Market
18. UK Mvabea Market
19. Germany Mvabea Market
20. France Mvabea Market
21. Eastern Europe Mvabea Market
22. North America Mvabea Market
23. USA Mvabea Market
24. Canada Mvabea Market
25. South America Mvabea Market
26. Middle East Mvabea Market
27. Africa Mvabea Market
28. Mvabea Market Competitive Landscape and Company Profiles
29. Global Mvabea Market Pipeline Analysis
33. Mvabea Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Mvabea Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on mvabea market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for mvabea? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mvabea market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Product Type: Mvabea (MVA-BN-Filo); Zabdeno (Ad26.ZEBOV)2) by Application: Ebola Virus Disease Prevention; Outbreak Control Efforts
3) by End User: Government Organizations; Healthcare Providers; Research Institutions
Key Companies Mentioned:Johnson & Johnson
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Johnson & Johnson
